S-1: HCW Biologics Registers 3.4M Shares for Resale

Sentiment:

Registration Statement (S-1) 9 January 2026 4:49 PM

HCW Biologics Inc. filed an S-1 registration statement for the resale of up to 3.4 million common shares by selling stockholders, signaling potential dilution and highlighting ongoing financial and regulatory challenges.

Delay expectedThe supply agreement for HCW9218 from ImmunityBio, which was a condition of the Settlement Agreement and due by January 2025, is not yet in place, delaying the ability to continue clinical development of HCW9218 in non-oncology indications.The $7.0 million upfront license fee from WY Biotech (now Trimmune) for HCW11-006 was initially due by May 13, 2025, then extended to September 30, 2025, and is now contingent on Trimmune's financing by January 16, 2026.The company's ability to begin clinical trials may be delayed or denied altogether pending FDA authorization of IND applications and negotiation of appropriate agreements with clinical sites.Legal proceedings related to unpaid construction invoices for the Miramar facility, involving BE&K Building Group and Fisk Electric Company, have a pretrial conference set for November 20, 2026, and a jury trial in December 2026, indicating a prolonged resolution timeline.

Capital raiseThe company explicitly states the need to raise additional funding to continue as a going concern and advance its product candidates.Stockholders approved the use of an equity line of credit (ELOC Purchase Agreement with Square Gate Capital Master Fund, LLC – Series 4) to raise up to $40.0 million through sales of common stock.The company may receive up to $7,279,188 in gross proceeds from the cash exercise of New Warrants and up to $3,290,040 from the cash exercise of Conversion Warrants.The Amended and Restated License Agreement with Trimmune includes a $7.0 million upfront license fee, with half ($3.5 million) in cash and half in transferable equity, contingent on Trimmune's financing.The company is in active discussions for a license agreement with major biologics manufacturing companies for non-core molecules, which could provide a source of capital.Future financing may be sought through public or private equity, debt financing, business development transactions, or other forms of financing.

Worse than expectedSubstantial doubt exists about the company's ability to continue as a going concern, with only $1.1 million in cash and cash equivalents as of September 30, 2025, against significant outstanding liabilities.The company is non-compliant with Nasdaq listing rules and has been granted an extension, indicating ongoing regulatory challenges that could impact its listing status.Significant outstanding liabilities, including $12.3 million in unpaid legal fees and $2.7 million in construction obligations, have led to legal proceedings, diverting resources and creating financial strain.A key licensing agreement for HCW11-006, expected to provide a $7.0 million upfront fee, has faced multiple delays and is now contingent on a third party's financing, introducing uncertainty to a critical funding source.Delays in securing a supply agreement for HCW9218 from ImmunityBio are hindering the progression of Phase 2 clinical trials for this product candidate.

Summary

A registration statement was filed for the resale of up to 3,400,033 shares of common stock by selling stockholders, including 253,083 Conversion Shares and 3,020,410 Warrant Shares from new warrants issued to Armistice Capital Master Fund Ltd.
The company will not receive any proceeds from the sale of these shares by selling stockholders, but may receive up to $7,279,188 from cash exercise of New Warrants and up to $3,290,040 from cash exercise of Conversion Warrants.
HCW Biologics is a clinical-stage biopharmaceutical company developing immunotherapies for diseases promoted by chronic inflammation, including age-related and senescence-associated diseases, utilizing its TOBI and TRBC platforms.
The lead product candidate, HCW9302, commenced a Phase 1 clinical trial for alopecia areata (an autoimmune disorder) with the first patient dosed on November 18, 2025.
As of September 30, 2025, the company had $1.1 million in cash and cash equivalents and cumulative net losses of $106.5 million, raising substantial doubt about its ability to continue as a going concern.
The company faces Nasdaq compliance issues, having received notice of non-compliance with the Equity Rule (5550(b)(1)) as of June 30, 2025, and was granted an extension until December 31, 2025, for the Equity Rule and February 16, 2026, for all other rules.
Significant outstanding obligations total $19.4 million in accounts payable as of September 30, 2025, including $12.3 million for legal fees from a settled arbitration and $2.7 million for manufacturing facility construction.
A license agreement with Beijing Trimmune Biotech Co., Ltd. (Trimmune) for HCW11-006, involving a $7.0 million upfront fee ($3.5 million cash, $3.5 million equity), is contingent on Trimmune's financing by January 16, 2026, following multiple delays.
A 1-for-40 reverse stock split was effective on April 11, 2025, approved by stockholders and the board.

Sentiment

Score: 3

Explanation: The company faces severe financial instability, explicitly stating 'substantial doubt about our ability to continue as a going concern' with only $1.1 million in cash and cash equivalents as of September 30, 2025, against $19.4 million in accounts payable. Ongoing Nasdaq non-compliance, significant dilution from warrant exercises, and delays in key licensing payments further compound the negative outlook. While there is clinical progress, the immediate financial risks and operational challenges are overwhelming, making the stock a high-risk, speculative investment with a strong likelihood of further decline.

Positives

The first patient was dosed in a Company-sponsored Phase 1 clinical trial for HCW9302 in patients with an autoimmune disorder (alopecia areata) on November 18, 2025.
A Settlement Agreement with ImmunityBio in July 2024 eliminated uncertainty from previous arbitration proceedings and provided clarity for the company's clinical development strategy.
The company secured a new Amended and Restated License, Research and Co-Development Agreement with Trimmune for HCW11-006, which includes a $7.0 million upfront license fee (half cash, half equity).
Potential to receive up to $10.57 million in gross proceeds from the cash exercise of New Warrants and Conversion Warrants.
Regained compliance with several Nasdaq listing rules (bid price, public float, market value of publicly held shares) by May 13, 2025, and initially with the Equity Rule by June 26, 2025.

Negatives

There is substantial doubt about the company's ability to continue as a going concern, with only $1.1 million in cash and cash equivalents as of September 30, 2025, and cumulative net losses of $106.5 million.
The company is non-compliant with Nasdaq Listing Rule 5550(b)(1) (Equity Rule) as of June 30, 2025, and faces a deadline of December 31, 2025, to regain compliance for this rule and February 16, 2026, for all other rules.
Outstanding obligations total $19.4 million in accounts payable as of September 30, 2025, including $12.3 million for legal fees and $2.7 million for construction of a manufacturing facility.
Legal proceedings have been initiated by contractors (BE&K Building Group and Fisk Electric Company) related to unpaid construction invoices, with a jury trial set for December 2026.
A supply agreement for HCW9218 from ImmunityBio, due by January 2025, is not yet in place, delaying Phase 2 clinical trials for non-oncology indications.
The $7.0 million upfront license fee from Trimmune has been subject to multiple delays and is now contingent on Trimmune's financing by January 16, 2026; failure to close will result in intellectual property rights reverting to the company.
The resale of up to 3,400,033 shares of common stock by selling stockholders is expected to cause substantial dilution and could lead to a decline in the stock price.
The Wugen License, a source of potential royalty revenues, was voluntarily suspended for one year starting May 29, 2025.

Risks

The exercise, issuance, and sale of Warrant Shares, Conversion Shares, and shares from Conversion Warrants may cause substantial dilution and a decline in the common stock price.
The potential issuance and sale of shares under the Equity Purchase Agreement with Square Gate Capital Master Fund, LLC – Series 4 (ELOC Purchase Agreement) may cause substantial dilution.
The need for future financing may result in the issuance of additional securities, causing further dilution to investors.
The company has incurred significant financial losses since inception and expects to incur losses for the foreseeable future, with no products approved for commercial sale and no assurance of achieving profitability.
There is substantial doubt regarding the company's ability to continue as a going concern based on its cash and cash equivalents of $1.1 million as of September 30, 2025.
Failure to obtain capital when needed may force delays, limits, or termination of product development efforts or other operations.
Raising additional capital may dilute existing shareholders, restrict operations, or cause the company to relinquish valuable rights.
Failure to maintain an effective system of disclosure controls and internal control over financial reporting could impair the ability to produce timely and accurate financial statements.
Significant obligations remain from legal fees incurred in prior arbitration proceedings ($12.3 million unpaid as of September 30, 2025).
The company is unable to progress into Phase 2 clinical trials for HCW9218 (cancer indications) due to the Settlement Agreement and a delay in securing a supply agreement for clinical materials from ImmunityBio.
The company is non-compliant with Nasdaq Listing Rule 5550(b)(1) as of June 30, 2025, and there is no assurance that the Nasdaq Hearings Panel will grant continued listing or that compliance will be achieved within the required timeframe.
The ability to begin clinical trials may be delayed or denied altogether pending FDA authorization of IND applications and negotiation of agreements with clinical sites.
Clinical trials may fail to demonstrate the safety and efficacy of product candidates, preventing, delaying, or limiting regulatory approval and commercialization.
Preliminary, topline, or interim data from clinical trials may change as more patient data becomes available and are subject to audit and verification procedures.
The development and commercialization of biopharmaceutical products are subject to extensive, lengthy, time-consuming, and inherently unpredictable regulatory approval processes.
Clinical drug development is a lengthy and expensive process with uncertain timelines and outcomes; prolonged or delayed trials could prevent or delay commercialization.
Even if product candidates obtain regulatory approval, the company will be subject to ongoing obligations and continued regulatory review, resulting in significant additional expense, labeling restrictions, market withdrawal, and penalties for non-compliance.
Reliance on patents and other intellectual property rights to protect technology is challenging, time-consuming, and costly; failure to defend, protect, or enforce these rights adequately could harm the ability to compete.
Reliance on third parties to manufacture product candidates carries risks, including failure to produce acceptable drug substance or obtain regulatory authorization, which may delay or impair clinical trials, approvals, or commercialization.
Information technology systems, or those used by third-party contractors or consultants, may fail or suffer security breaches, which could adversely affect the business.
Inability to identify licensees for out-licensing internally developed molecules could lower return on investments and increase the need for external funding.
Difficulties in managing growth due to expected expansion in employees and operations, limited financial resources, and management experience.
Risks related to climate change, including extreme weather impacting the supply chain and operations.
Potential exposure to costly and damaging product liability claims, with insurance possibly not covering all damages.
Changes in regulatory policies or new legislation (e.g., IRA, Project Optimus) could increase the difficulty and cost of obtaining approval and commercializing products, and affect pricing.
Operating in highly competitive and rapidly changing industries may result in competitors developing products before or more successfully.
Failure to successfully identify, develop, and commercialize additional product candidates could impair growth.
Even if approved, products may not gain market acceptance, impacting revenue generation.
Lack of marketing, sales, or distribution infrastructure, with substantial risks in establishing or outsourcing this function.
Dependence on a single third-party manufacturer for cGMP production; loss of this manufacturer could negatively impact development.
Reliance on third parties for biological materials, which can be difficult to produce and have variability.
Reliance on third parties, including independent clinical investigators, to conduct preclinical studies and clinical trials; failure to perform could substantially harm the business.
Failure to realize the benefits of existing or future co-development or out-licensing arrangements, or failure to enter into new strategic relationships.
Claims challenging the inventorship or ownership of patents and other intellectual property.
Reliance on trade secrets and proprietary know-how, which can be difficult to trace and enforce.
Potential liability related to the privacy of health information (e.g., HIPAA, HITECH, GDPR, CCPA, CPRA).
Reduced reporting requirements as an emerging growth company may make common stock less attractive to investors.
Stock price may be volatile or decline regardless of operating performance, resulting in substantial losses for investors.
Principal stockholders and management own a meaningful percentage of stock, which may allow them to influence matters subject to stockholder approval.
Potential future sales pursuant to registration rights and Rule 144 may depress the market price for common stock.
FINRA sales practice requirements may limit a stockholder's ability to buy and sell common stock.
Volatility in the company's share price could subject the company to securities class action litigation.
A short squeeze due to a sudden increase in demand for shares that largely exceeds supply could lead to extreme price volatility.
Increases in market interest rates may cause potential investors to seek higher returns and reduce demand for common stock.
If securities or industry analysts do not publish research or reports, or publish negative reports, the company's share price and trading volume could decline.
No anticipated cash dividends; capital appreciation, if any, would be the sole source of gain.
Future offerings of debt and/or preferred equity securities could adversely affect the market price of common stock.
Anti-takeover provisions in the charter and bylaws, as well as provisions of Delaware law, could impair a takeover attempt.
Exclusive forum provisions in the charter could limit stockholders' ability to obtain a favorable judicial forum for disputes.

Future Outlook

The company expects to incur significant operating losses for the foreseeable future and will require substantial additional funding to advance product candidates and sustain operations. Expenses are anticipated to increase with ongoing preclinical and clinical studies, manufacturing scale-up, and overall growth. A strategy includes funding operations partly through revenues from out-licensing non-core molecules. The company intends to expand its capabilities, including developing its own manufacturing facility. It anticipates that healthcare reform measures, such as the ACA and IRA, will lead to more rigorous coverage criteria and downward pressure on product pricing. No cash dividends are expected in the foreseeable future.

Management Comments

Our expertise is in immunotherapeutic treatments and our clinical development pipeline will remain so.
Our focus continues to be to develop protein-based immunotherapies that are administered by subcutaneous injection.
We remain focused on diseases promoted by chronic inflammation driven by senescence, including cancer, especially age-related diseases.
The diseases we will target will have no curative FDA approved treatments.
We have selected programs that include life-threatening diseases, such as pancreatic and ovarian cancer, as well as quality-of-life indications, such as alopecia areata and senile lentigo.
HCW9302 will remain one of our lead product candidates.
Future drug discovery and new drug development will be based on TRBC Molecules.
We believe that our cash and cash equivalents as of September 30, 2025, will not be sufficient for the Company to continue as a going concern for at least one year from the issuance date of the financial statements.

Industry Context

The company operates in the highly competitive and rapidly changing biotechnology and pharmaceutical industries, focusing on immunotherapies for chronic inflammation and age-related diseases, an area with growing scientific interest. Its development of novel immunotherapeutic approaches and senotherapeutic drugs aims to address areas where small molecule-based approaches have seen limited clinical success. The industry is subject to extensive and unpredictable regulatory processes, as well as increasing pressures from healthcare cost containment initiatives like the ACA and IRA, which could impact future product pricing and market access. Mergers and acquisitions within the sector continue to concentrate resources among competitors, intensifying the competitive landscape.

Comparison to Industry Standards

The company's CEO, Dr. Hing C. Wong, has a track record of success in the immunotherapy space, having discovered and developed Anktiva (ALT-803), an IL-15 agonist receptor, which was sold to ImmunityBio, Inc. in 2017 for $1.0 billion and received FDA approval for a bladder cancer indication in 2024. This provides a strong internal benchmark for management's capability in bringing immunotherapeutics to market.
The company's strategy to target diseases with 'no curative FDA approved treatments' aligns with a common industry approach of focusing on high-unmet-medical-need areas, which can command premium pricing and faster regulatory pathways if successful.
The company highlights that 'there has been limited clinical success in targeting senescent cell accumulation or aberrant inflammasome activity using small molecule-based approaches,' positioning its novel immunotherapeutic approach as a potential differentiator against existing or developing therapies in the senotherapeutic drug class.

Corporate Governance

Change Type	Description	Effective Date	Impact Assessment
Capital Structure Change	A 1-for-40 reverse stock split of all outstanding shares of Common Stock was approved by stockholders and the Board, effective April 11, 2025.	2025-04-11	Retrospectively adjusted share numbers and price per share amounts, but did not affect par value or rights/privileges of holders. Aims to regain Nasdaq compliance.
Financing Authorization	Stockholders approved the use of an equity line of credit to raise up to $40.0 million through sales of Common Stock.	2025-03-31	Provides a mechanism for future capital raises, but also introduces potential for significant shareholder dilution.
Debt Conversion Authorization	Stockholders approved the execution of principal terms for the conversion of up to approximately $6.9 million of outstanding principal of Secured Notes into shares of Common Stock.	2025-03-31	Reduced debt obligations but resulted in the issuance of Conversion Shares and Warrants, contributing to potential dilution.
Anti-Takeover Provisions	The company's charter contains provisions such as no cumulative voting, the Board's right to fill vacancies, and a prohibition on stockholder action by written consent, which may discourage unsolicited takeover proposals.	N/A	May make it more difficult to remove management or for stockholders to effect changes, potentially depriving stockholders of opportunities to sell shares at a premium.
Exclusive Forum Provisions	The charter designates the Court of Chancery of the State of Delaware as the exclusive forum for certain internal corporate claims and federal district courts for Securities Act claims.	N/A	Aims to provide consistency in legal interpretations but may limit stockholders' ability to choose a favorable judicial forum and could increase litigation costs.
Indemnification Policy	The company has entered into indemnification agreements with each director and officer, and its charter and bylaws require indemnification to the fullest extent permitted by Delaware law.	N/A	Protects directors and officers from personal liability, but may reduce the likelihood of derivative litigation and could result in the company bearing settlement and damage awards.
Related Party Transaction Policy	A written policy requires Audit Committee review and approval for material related party transactions (exceeding $120,000 or 1% of average total assets).	2021-06-10	Aims to ensure related party transactions are fair and in the best interest of the company and its stockholders, mitigating potential conflicts of interest.

Legal Proceedings

A Settlement Agreement was reached in July 2024 with Altor BioScience, LLC, NantCell, Inc., and ImmunityBio, Inc., resolving previously disclosed arbitration proceedings.
The company has significant obligations of $12.3 million in unpaid legal fees as of September 30, 2025, incurred for its defense and the defense of its CEO in the long-running arbitration.
A forbearance agreement was entered into with BE&K Building Group on January 22, 2025, regarding construction obligations for the Miramar facility.
On April 17, 2025, the company received a summons and complaint from BE&K Building Group in Florida Circuit Court related to unpaid construction invoices.
On April 28, 2025, the company received a summons and complaint from Fisk Electric Company (a defendant in the BE&K Complaint) in the same court, also related to construction.
On August 8, 2025, B&I Contractors, Inc., another defendant, filed a motion for summary judgment regarding foreclosure of a construction lien.
The BE&K and Fisk cases are being consolidated, with a pretrial conference set for November 20, 2026, and a jury trial in the first two weeks of December 2026.
The company has indemnification obligations for claims against its founder and CEO, Dr. Hing C. Wong, from a former employer, and is advancing defense costs, with the matter ongoing.

Related Party Transactions

**Private Placement (February 20, 2024)**: The company sold 44,643 shares of Common Stock at $56.00 per share for an aggregate of $2.5 million to certain officers and directors, including Rebecca Byam (CFO), Dr. Hing C. Wong (CEO), and Scott Garrett (Chairman of the Board).
**Secured Note Financing (as of October 31, 2024)**: Of approximately $6.9 million in senior secured promissory notes issued, $2.9 million was purchased by members of the board and executive officers, including Dr. Hing C. Wong ($2,405,000), Rebecca Byam ($220,000), Scott T. Garrett ($140,000), Gary M. Winer ($60,000), Lee Flowers ($25,000), and Rick S. Greene ($25,000).
**Conversion of Secured Notes (May 7, 2025)**: Holders of $6.6 million of the Secured Notes, including related parties, converted their notes into 253,083 unregistered Conversion Shares and warrants to purchase an additional 126,540 shares of Common Stock. Dr. Hing C. Wong, for example, received 92,500 Conversion Shares and 46,250 shares issuable upon exercise of Conversion Warrants.
**Convertible Bridge Notes (as of May 7, 2025)**: The company issued $270,000 principal amount of unsecured convertible promissory notes, with investors including Hing C. Wong ($60,000), Scott T. Garrett ($100,000), and Gary M. Winer ($10,000).
**Indemnification Agreements**: The company has entered into indemnification agreements with each of its directors and officers, and its bylaws and certificate of incorporation require indemnification for certain claims.

Stakeholder Impact

**Shareholders**: Face significant dilution risk from the resale of 3.4 million shares and potential future capital raises. The company's 'going concern' doubt, Nasdaq compliance issues, and legal challenges pose substantial risks to stock price and investment value. No cash dividends are anticipated, making capital appreciation the sole source of gain.
**Employees**: Potential for job insecurity if funding issues lead to delays or termination of product development programs. While growth plans suggest increased hiring, financial constraints could limit this. Employees are also subject to risks of misconduct or fraud.
**Customers (future)**: Delays in clinical trials and regulatory approval could postpone the availability of the company's novel immunotherapies, impacting patients seeking treatments for chronic inflammation and age-related diseases.
**Suppliers/Creditors**: The company's $19.4 million in accounts payable, including $2.7 million for construction, indicates payment risks. Ongoing legal proceedings from contractors highlight disputes over unpaid invoices.
**Regulatory Authorities**: The company is under scrutiny due to Nasdaq non-compliance and must adhere strictly to FDA regulations for clinical trials and product development, which can be lengthy and costly.

Next Steps

Regain compliance with Nasdaq Equity Rule by December 31, 2025.
Regain compliance with all other Nasdaq continued listing rules by February 16, 2026.
Trimmune to finalize financing and close the Amended and Restated License Agreement by January 16, 2026.
Depending on Phase 1 results for HCW9302, initiate multi-dose studies in expanded cohorts of patients with alopecia areata and other inflammatory dermatological conditions.
Secure supply of clinical materials for HCW9218 to progress into Phase 2 clinical trials for non-oncology indications.
Continue to implement and improve managerial, operational, and financial systems to manage anticipated growth.
Recruit and train additional qualified personnel.
Identify, select, and develop promising additional product candidates and therapeutics.
Potentially establish own sales and marketing infrastructure or outsource this function if product candidates are approved.
Continue to pursue out-licensing agreements for non-core programs and assets.
Address legal proceedings related to construction obligations, with a pretrial conference set for November 20, 2026, and a jury trial in December 2026.

Key Dates

Date	Description
2019-10-09	Rebecca Byam Employment Agreement.
2020-12-24	Exclusive License Agreement with Wugen, Inc.
2021-06-10	Audit Committee Charter, Compensation Committee Charter, and Related Party Transactions Policy adopted and approved.
2021-07-06	Peter Rhode Employment Agreement.
2021-07-09	2019 Equity Incentive Plan, First Amendment to 2019 Equity Incentive Plan, 2021 Equity Incentive Plan, and Executive Incentive Bonus Plan.
2021-07-26	Amended and Restated Certificate of Incorporation and Amended and Restated Bylaws.
2022-08-15	Loan Agreement and Mortgage and Security Agreement with Cogent Bank.
2022-08-19	Capital on Demand Sales Agreement with Jones Trading Institutional Services LLC.
2022-08-26	Shelf registration statement on Form S-3 (File No. 333-266991) declared effective.
2024-02-20	Private placement of 44,643 shares of Common Stock to officers and directors for $2.5 million.
2024-03-28	Senior Secured Note Purchase Agreement and Promissory Note.
2024-07-02	Amended and Restated Senior Secured Note Purchase Agreement and Pledge Agreement.
2024-07-13	Settlement Agreement with Altor BioScience, LLC, NantCell, Inc., and ImmunityBio, Inc.
2024-09-19	Dismissed Grant Thornton as independent accounting firm and engaged Crowe LLP.
2024-09-30	First Amendment to the Amended and Restated Senior Secured Note Purchase Agreement.
2024-10-31	Issued approximately $6.9 million in principal amount of senior secured promissory notes.
2024-11-14	Quarterly Report on Form 10-Q filed.
2024-11-18	Securities Purchase Agreement with Armistice Capital Master Fund Ltd.
2024-11-19	Entered into License, Research and Co-Development Agreement with WY Biotech Co., Ltd. (amended).
2024-11-20	Registered direct offering closed, generating approximately $6.9 million gross proceeds.
2024-12-31	Arbitration with ImmunityBio dismissed.
2025-01	FDA lifted clinical hold on Phase 1 study of HCW9302.
2025-01-22	Entered into a forbearance agreement with BE&K Building Group.
2025-02-20	Entered into an Equity Purchase Agreement with Square Gate Capital Master Fund, LLC – Series 4.
2025-03-12	Issued 9,616 shares of Common Stock to Square Gate as a Commitment Fee.
2025-03-17	Letter Agreement to the License, Research and Co-Development Agreement with WY Biotech Co. Ltd.
2025-03-28	Annual Report on Form 10-K for the year ended December 31, 2024, filed.
2025-03-31	Stockholders approved a reverse stock split, use of equity line of credit, and conversion of secured notes. Board approved a 1-for-40 reverse stock split.
2025-04-01	Filed a Certificate of Amendment to effect a reverse stock split.
2025-04-11	Reverse Stock Split became effective at 12:01 a.m. Eastern Time; Common Stock commenced trading on a Reverse-Stock-Split-adjusted basis.
2025-04-16	Registration Statement for resale of Armistice Warrants and Square Gate Commitment Shares became effective.
2025-04-17	Received a summons and complaint from BE&K Building Group.
2025-04-28	Received a summons and complaint from Fisk Electric Company.
2025-05-01	Entered into a Second Amendment to the Secured Note purchase agreement.
2025-05-07	Holders of approximately $6.6 million of Secured Notes converted their notes into equity, resulting in the issuance of 253,083 Conversion Shares and 126,540 Conversion Warrants.
2025-05-13	Regained compliance with Nasdaq bid price, public float, and market value of publicly held shares requirements. Registration statement on Form S-1 (File No. 333-287136) declared effective. Technical report delivered to WY Biotech.
2025-05-15	Completed a follow-on public offering, generating approximately $4.0 million gross proceeds. Amended exercise price of Purchase Warrants from $41.20 to $7.45 per share. Quarterly Report on Form 10-Q filed.
2025-05-29	Voluntarily suspended the Wugen License for a period of one year.
2025-05-30	WY Biotech notified the company that it completed due diligence and elected to continue with the exclusive worldwide license.
2025-06-26	Announced compliance with Nasdaq Listing Rule 5550(b)(1) (Equity Rule).
2025-06-30	Company was non-compliant with Nasdaq Listing Rule 5550(b)(1) (Equity Rule).
2025-07-13	Second Letter Agreement to the License, Research and Co-Development Agreement with WY Biotech Co. Ltd.
2025-08-08	B&I Contractors, Inc. filed a motion for summary judgment regarding foreclosure of a construction lien.
2025-08-14	First Amendment to the Equity Purchase Agreement with Square Gate Master Fund – Series 4.
2025-08-18	Quarterly Report on Form 10-Q filed.
2025-08-19	Received written notice from Nasdaq Listing Qualifications Staff regarding non-compliance with the Equity Rule.
2025-08-26	Timely requested a hearing before the Nasdaq Hearings Panel.
2025-09-02	WY Biotech informed the company of likely failure to meet the amended payment date for the $7.0 million license fee.
2025-09-25	Nasdaq Hearings Panel hearing took place.
2025-09-30	Latest agreed date for payment of the $7.0 million license fee from WY Biotech. Cash and cash equivalents were $1.1 million. Cumulative net losses were $106.5 million. Accounts payable totaled $19.4 million.
2025-10-13	Nasdaq Panel granted an extension of time to regain compliance with all continued listing rules.
2025-11-14	Quarterly Report on Form 10-Q filed.
2025-11-17	Entered into an Amended and Restated License, Research and Co-Development Agreement with Beijing Trimmune Biotech Co., Ltd. First patient dosed in a Phase 1 clinical trial for HCW9302.
2025-11-19	Entered into a warrant inducement agreement with Armistice, resulting in approximately $4.0 million gross proceeds and the issuance of New Warrants for 3,020,410 shares.
2025-12-16	Date used for calculating the registration fee based on the average of high and low sale prices of Common Stock on Nasdaq.
2025-12-31	Deadline to demonstrate compliance with the Nasdaq Equity Rule.
2026-01-06	Last quoted sale price for common stock was $1.20 per share. 3,279,812 shares of common stock outstanding.
2026-01-08	Date of Clark Hill PLC opinion letter.
2026-01-09	Filing date of the S-1 Registration Statement. Date of consent letters from Grant Thornton LLP and Crowe LLP.
2026-01-16	Deadline for Trimmune to close the A&R License Agreement; if not, intellectual property and rights revert to the company.
2026-02-16	Deadline to demonstrate compliance with all other Nasdaq continued listing rules.
2026-03-27	Maturity date for the Senior Secured Promissory Notes.
2026-06-23	End of the Panel Monitor period for Nasdaq compliance.
2026-11-20	Pretrial conference for the BE&K and Fisk Complaints.
2026-12	Jury trial for the BE&K and Fisk Complaints scheduled for the first two weeks of December.

Recommendation

strong sell

The company faces severe financial instability, explicitly stating 'substantial doubt about our ability to continue as a going concern' with only $1.1 million in cash and cash equivalents as of September 30, 2025, against $19.4 million in accounts payable. Ongoing Nasdaq non-compliance, significant dilution from warrant exercises, and delays in key licensing payments further compound the negative outlook. While there is clinical progress, the immediate financial risks and operational challenges are overwhelming, making the stock a high-risk, speculative investment with a strong likelihood of further decline.

Keywords

Biopharmaceutical, Immunotherapy, Clinical-stage, Chronic inflammation, Age-related diseases, Senescence, Cancer, Autoimmune, HCW9302, TRBC platform, TOBI platform, Nasdaq compliance, S-1 filing, Warrant resale, Dilution, Going concern, Capital raise, SEC

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.